Our Company has been granted patents for our products in most key markets, including Australia, China, Japan, South Korea, European Union (Germany, France, United Kingdom, Italy, Spain, Netherlands, Turkey, Switzerland, Sweden, Poland, Belgium, Austria, Norway, Denmark, Ireland and Finland), Canada, South Africa, New Zealand, Singapore, Malaysia and Indonesia.
The claims of the patents cover a fast-dissolving oral dosage form for the release of a biologically active material in the oral cavity. Additionally, the particular dosage form may contain and deliver a wide range of biologically active materials and is not limited to a specific biologically active material. Methods for the production of the fast dissolving oral dosage form are also provided. See more on our WaferiXTM technology here.
Our patents strategy includes the use of the Patent Cooperation Treaty system with a view to obtain broad protection for our patent portfolio, which covers the WaferiXTM technology, our products as well as potential new formulations. We aim to secure intellectual property protection for our invention and products in all relevant jurisdictions, as and when necessary. In most countries, the term awarded for a granted patent is 20 years from the date of application.